The ESIP report reveals a continuous rise in national public spending on medicines across 15 EU member states and Norway, primarily driven by increasing drug costs rather than prescription volume. Cancer drugs are highlighted as the most expensive, with significant portions of healthcare budgets being strained. The introduction of novel therapies is contributing to rising expenditures, raising concerns about affordability and the effectiveness of new treatments. Teljes cikk (Euronews.com)